Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP261422.RAk_bVOUky4uhWmlcaKlPRQNp89-QpFXfkwVWr_36I-qA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP261422.RAk_bVOUky4uhWmlcaKlPRQNp89-QpFXfkwVWr_36I-qA130_assertion type Assertion NP261422.RAk_bVOUky4uhWmlcaKlPRQNp89-QpFXfkwVWr_36I-qA130_head.
- NP261422.RAk_bVOUky4uhWmlcaKlPRQNp89-QpFXfkwVWr_36I-qA130_assertion description "[Associations of epidermal growth factor (EGF) 61A>G, EGF receptor (EGFR) CA(14-22), cyclin D1 (CCND1) 932G>A, fragment-C gamma receptor (FCGR) 2A 535A>G and FCGR3A 818A>C polymorphisms with progression-free survival (PFS) and cetuximab-related skin toxicity were studied.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP261422.RAk_bVOUky4uhWmlcaKlPRQNp89-QpFXfkwVWr_36I-qA130_provenance.
- NP261422.RAk_bVOUky4uhWmlcaKlPRQNp89-QpFXfkwVWr_36I-qA130_assertion evidence source_evidence_literature NP261422.RAk_bVOUky4uhWmlcaKlPRQNp89-QpFXfkwVWr_36I-qA130_provenance.
- NP261422.RAk_bVOUky4uhWmlcaKlPRQNp89-QpFXfkwVWr_36I-qA130_assertion SIO_000772 20418097 NP261422.RAk_bVOUky4uhWmlcaKlPRQNp89-QpFXfkwVWr_36I-qA130_provenance.
- NP261422.RAk_bVOUky4uhWmlcaKlPRQNp89-QpFXfkwVWr_36I-qA130_assertion wasDerivedFrom befree-20150227 NP261422.RAk_bVOUky4uhWmlcaKlPRQNp89-QpFXfkwVWr_36I-qA130_provenance.
- NP261422.RAk_bVOUky4uhWmlcaKlPRQNp89-QpFXfkwVWr_36I-qA130_assertion wasGeneratedBy ECO_0000203 NP261422.RAk_bVOUky4uhWmlcaKlPRQNp89-QpFXfkwVWr_36I-qA130_provenance.